Add BrightSurf on Google Email

Adapting to clogged airways makes common pathogen resist powerful drugs

A recent study led by Dr. Lucas Hoffman found that Pseudomonas aeruginosa, a common pathogen in cystic fibrosis lung infections, can resist powerful antibiotics due to adapting to the clogged airways. The mutation enables the bacteria to thrive in viscous lung secretions and survive oxidative stress caused by antibiotic treatment.

SourceUniversity of Washington·JournalPLOS Pathogens·DateFeb 9, 2010

A trip to the candy store might help ward off rare, but deadly infections

Researchers found that glycyrrhizin improves the ability of damaged skin to produce antimicrobial peptides, which help prevent bacterial growth and infections. The study suggests that this compound could lead to lower death rates associated with burn-related infections.

SourceFederation of American Societies for Experimental Biology·JournalJournal of Leukocyte Biology·DateJan 4, 2010
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Strategy discovered for fighting persistent bacterial infections

Researchers have discovered a promising strategy to break down Pseudomonas biofilms, which form in cystic fibrosis patients and cause lung damage. A negatively charged molecule called aspartic acid polymer can disrupt the molecular bonds that hold together these difficult-to-treat infections.

SourceNational Jewish Health·JournalJournal of Medical Microbiology·DateMar 23, 2009

Biosynthetics production with detours

Researchers at Helmholtz-Zentrum für Infektionsforschung used computer models to identify genetic changes that increase biosynthetics production in Pseudomonas putida bacteria. The study, published in PLOS Computational Biology, aims to develop targeted methods for producing natural materials efficiently.

SourceHelmholtz Association·JournalPLOS Computational Biology·DateOct 31, 2008

New approach to treating cystic fibrosis lung infection shows promise

Researchers found that targeting Streptococcus milleri group (SMG) bacteria can disrupt Pseudomonas aeruginosa bacterial communities, leading to clinical benefits for patients. The approach has shown positive results in treating severe lung infections and may also be a treatment option for individuals with chronic lung infections.

SourceCanadian Cystic Fibrosis Foundation·JournalProceedings of the National Academy of Sciences·DateSep 22, 2008
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

Common food preservative might provide treatment for cystic fibrosis

Researchers discovered that a genetic mutation in Pseudomonas aeruginosa makes it susceptible to destruction by slightly acidified sodium nitrite, a common food preservative. This finding offers new hope for treating cystic fibrosis airway disease.

SourceUniversity of Cincinnati·JournalJournal of Clinical Investigation·DateJan 26, 2006
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Infection-fighting strategy backfires in cystic fibrosis

Researchers found that Pseudomonas aeruginosa biofilms develop faster in the presence of neutrophils, which are sent to fight infections. The biofilms become resistant to antibiotics and the immune system, leading to chronic lung damage and death.

SourceNational Jewish Health·JournalInfection and Immunity·DateJun 2, 2005

Pacifying bacteria prevents lethal post-op infections

Researchers have developed a protective coating that prevents deadly post-operative infections from Pseudomonas aeruginosa, a virulent pathogen that kills 100% of untreated mice. The coating, which works by pleasing the bacteria and preventing them from invading the host's bloodstream, has shown promising results in animal studies.

SourceUniversity of Chicago Medical Center·JournalGASTROENTEROLOGY·DateFeb 1, 2004
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

LSUHSC research shows drug blocks enzyme that activates bacterial and viral toxins

A new peptide, D6R, has been developed by LSUHSC researchers to block the action of an enzyme that activates toxic proteins in bacteria and viruses. The peptide was found to protect cells from lethal toxins without triggering a cytokine response, offering potential as a treatment for sepsis and other infections.

SourceLouisiana State University Health Sciences Center·JournalInfection and Immunity·DateNov 18, 2002

New center to study deadly microbial pathogens

The University of Washington has established a new center to combat deadly microbial pathogens, which threaten human health worldwide. Researchers will focus on developing treatments and vaccines for diseases caused by Pseudomonas aeruginosa, pathogenic protozoa, and other infectious agents.

SourceUniversity of Washington·DateMar 6, 2002

Cystic-fibrosis patients susceptible to pseudomonas cross-infection

Adults with cystic fibrosis (CF) are susceptible to cross-infection, including superinfection, from Pseudomonas aeruginosa. Chronic colonization occurs in up to 80% of CF patients, leading to increased illness and death. Genotypic changes in strains suggest social contact is a common mode of transmission.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 16, 2001
Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.

New Genome Project Hits WWW

A consortium of scientists has released a new genome sequencing project for the bacterium P. aeruginosa, which causes chronic lung infections in CF patients. The project aims to increase practical knowledge about the pathogen and develop new drugs for treatment.

SourceCystic Fibrosis Foundation·DateSep 18, 1997